Opioids are the most widely prescribed drugs for treatment of moderate to severe pain. They are also the most powerful analgesics for treatment of acute and chronic pain. However, their use is plagued by serious side effects, including abuse and addiction, severe withdrawal, constipation, respiratory depression, and death from overdose.


The CDC reports that over the past ten years mortality rates have declined for all serious medical conditions - except for death from prescription opioid abuse, which has risen dramatically since 1990. According to the CDC, "this is a major public health problem that is getting worse, and getting worse rapidly." Phoenix PharmaLabs intends to bring drugs to market that will reverse that trend.


Phoenix PharmaLabs, Inc. (PPL) is a privately held, IND-stage drug development company focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. The company was founded in 2002 with the mission to bring its new class of opioid pain therapies and addiction treatment alternatives to the Clinic.


PPL has designed a new class of opioid drugs with unique opiate receptor characteristics never before seen. Unlike other opioids such as morphine, oxycodone, hydrocodone, etc. which primarily stimulate the mu receptor, PPL's drugs have high binding affinity at all three opiate receptors (mu, kappa and delta) and relatively more balanced receptor activity than other opioids. This profile results in the first ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects.


Extensive animal testing by the NIH demonstrated that the company's drugs provide very high levels of analgesic potency (10 to 20 times greater than morphine) without addiction liability or any serious side effects such as respiratory depression, dysphoria, constipation, or death from overdose - even at 350x dosage. The drugs are orally active and inexpensive to manufacture (using PPL's patented process). They also offer very promising use for addiction therapy as a preferred substitute for methadone and buprenorphine.


We intend to continue to seek complimentary business relationships, out-license opportunities and/or co-development opportunities with both domestic and overseas partners as we continue to advance our drug candidates through clinical trials.

News Flash

Patent Awarded
"Use of PPL opiate in the treatment of opiate addiction." ...
More details...